US2020237755A1PendingUtilityA1

Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders

74
Assignee: OTSUKA PHARMA CO LTDPriority: Apr 14, 2005Filed: Apr 14, 2020Published: Jul 30, 2020
Est. expiryApr 14, 2025(expired)· nominal 20-yr term from priority
C07D 409/14C07D 409/04A61K 31/496C07D 409/12A61K 9/2059A61K 9/2054A61P 25/24A61P 25/14A61P 25/18A61P 25/32A61P 25/22A61P 25/16A61P 25/28C07D 405/12A61P 25/00
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A method for treating or preventing a central nervous system disorder comprising administering a heterocyclic compound of the formula (1): 
       
         
           
           
               
               
           
         
         wherein rind Q represented by 
       
       
         
           
           
               
               
           
         
         represents 
       
       
         
           
           
               
               
           
         
         wherein 
       
       
         
           
           
               
               
           
         
         represents —NH—CH 2 —, —N═CH—, —CH 2 —NH— or —CH═N—; and the carbon-carbon bond    
         between the 3-position and 4-position of the heterocyclic skeleton containing Z and Y represents a single bond or a double bond;
 the ring Q may have at least one substituent selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkyl group, an aryl group, an aryl lower alkyl group, an aryl lower alkoxy group, an arylcarbonyl group, a lower alkenyloxy group, a lower alkanoyl group, a lower alkanoyloxy group, a cycloalkyl group, a cycloalkyl lower alkyl group, a halogen atom, a carbamoyl group which may have a lower alkyl group, a carboxy group, a lower alkoxycarbonyl group, an amino group which may have a lower alkanoyl group, a nitro group, a hydroxy lower alkyl group, an amino lower alkyl group which may have a lower alkyl group, a thienyl group, a saturated 3- to 8-membered heteromonocyclic group containing 1 to 2 nitrogen atoms-substituted lower alkyl group and an oxo group; 
 R 2  represents a hydrogen atom or a lower alkyl group; and 
 A represents —O-A 1 - (wherein A 1  represents an alkylene group which may be substituted with a hydroxy group (wherein the alkylene group may contain one oxygen atom) or a lower alkenylene group) or a lower alkylene group; 
 provided that when A represents a lower alkylene group, the ring Q represents a bicyclic group selected from the group consisting of: 
 
       
       
         
           
           
               
               
           
         
         wherein the carbon-carbon-bond    
         represents a single bond or a double bond or a salt thereof to a human or animal. 
       
     
     
         16 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.